CAMBRIDGE, Mass., Aug. 15 /PRNewswire/ -- ETEX Corporation, an advanced biomaterials company, announced today that it has launched an innovative orthobiologic, EquivaBone(TM). EquivaBone(TM) is a bone graft substitute that remodels and is replaced with new bone during the healing process.
Brian Ennis, President and CEO of ETEX Corporation, states, “ETEX is excited to offer surgeons a best-in-class combination product that provides optimal osteoinductive and osteoconductive performance. The market demands a combination DBM product that not only flows but sets hard for a complete defect fill. This product is the culmination of years of research and development. Based on initial customer feedback, we anticipate a robust market response.”
EquivaBone(TM) is a proprietary combination of osteoinductive Demineralized Bone Matrix (DBM) and ETEX’s osteoconductive nanocrystalline calcium phosphate. ETEX is proud to offer the first combination product that is both moldable and injectable and sets hard once implanted. In addition, osteoinductivity of the DBM is certified after sterilization, by lot, for the entirety of shelf life.
Both trauma and spine fusion data were included in the 510k submission which received FDA clearance on April 28, 2008. EquivaBone(TM) is intended for use in filling bone voids or defects of the skeletal system (including extremities, pelvis, and spine) that are not intrinsic to the stability of the bone structure.
ETEX will market EquivaBone(TM) through its direct distribution channel.
About ETEX Corporation
Established in 1989, ETEX Corporation develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes. A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems. For more information, visit www.etexcorp.com.
Source: ETEX Corporation
